Who are E. coli Nissle suspension's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): INF108F probiotic, Bifidobacterium animalis subsp. lactis, Lactobacillus brevis CD2 Lozenges.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/e-coli-nissle-suspension.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

E. coli Nissle suspension — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

E. coli Nissle suspension (E. coli Nissle suspension) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live biotherapeutic product (probiotic). Area: Gastroenterology.

marketed Live biotherapeutic product (probiotic) Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

E. coli Nissle suspension (E. coli Nissle suspension) — University of Hohenheim. E. coli Nissle is a live biotherapeutic probiotic strain that colonizes the gut and modulates the intestinal microbiota and immune system to promote gastrointestinal health.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
E. coli Nissle suspension TARGET	E. coli Nissle suspension	University of Hohenheim	marketed	Live biotherapeutic product (probiotic)
INF108F probiotic	INF108F probiotic	Massachusetts General Hospital	marketed	Live biotherapeutic product (probiotic)
Bifidobacterium animalis subsp. lactis	Bifidobacterium animalis subsp. lactis	University of Sao Paulo	phase 3	Live biotherapeutic product (probiotic)
Lactobacillus brevis CD2 Lozenges	Lactobacillus brevis CD2 Lozenges	Next Gen Pharma India Pvt. Ltd.	phase 3	Live biotherapeutic product (probiotic)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live biotherapeutic product (probiotic) class)

Massachusetts General Hospital · 1 drug in this class
Next Gen Pharma India Pvt. Ltd. · 1 drug in this class
University of Hohenheim · 1 drug in this class
University of Sao Paulo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). E. coli Nissle suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/e-coli-nissle-suspension. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab